source
- Chiesi signs $1.9B deal to acquire KalVista and its approved drugChiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KAL…Endpoints · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and moreThe FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials conducted by AstraZeneca and AmgenSTAT · 3mo ago↗ source
- Should pharma be swinging bigger with AI? One top researcher wants to tryRIO DE JANEIRO — Kyunghyun Cho says he's a free man once again. He makes that observation, semi-jokingly, while looking over countless rows of poster presentations on the sidelines of the Internati…